Integrated OTC Stock Alpha and Beta Analysis

INBP -  USA Stock  

USD 1.09  0.03  2.83%

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Integrated Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Integrated Biopharma over a specified time horizon. Remember, high Integrated Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Please see Integrated Biopharma Backtesting, Integrated Biopharma Valuation, Integrated Biopharma Correlation, Integrated Biopharma Hype Analysis, Integrated Biopharma Volatility, Integrated Biopharma History and analyze Integrated Biopharma Performance.

Integrated Beta 

 
Refresh
Please note that although Integrated Biopharma alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, Integrated Biopharma did 0.09  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Integrated Biopharma stock's relative risk over its benchmark. Integrated Biopharma has a beta of 0.38  . Let's try to break down what Integrated's beta means in this case. As returns on the market increase, returns on owning Integrated Biopharma are expected to decrease at a much lower rate. During the bear market, Integrated Biopharma is likely to outperform the market.
Integrated Biopharma Book Value per Share is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Book Value per Share of 0.48. As of 20th of October 2021, Enterprise Value over EBIT is likely to grow to 5.51, while Tangible Asset Value is likely to drop about 23.5 M.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

Enterprise Value

34.28 MillionShare

Integrated Biopharma Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Integrated Biopharma market risk premium is the additional return an investor will receive from holding Integrated Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Integrated Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Integrated Biopharma's performance over market.
α0.09   β-0.38
90 days against DJI

Integrated Biopharma expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Integrated Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Integrated Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Integrated Biopharma Market Price Analysis

Market price analysis indicators help investors to evaluate how Integrated Biopharma otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Integrated Biopharma shares will generate the highest return on investment. By understating and applying Integrated Biopharma otc stock market price indicators, traders can identify Integrated Biopharma position entry and exit signals to maximize returns.

Integrated Biopharma Return and Market Media

The median price of Integrated Biopharma for the period between Thu, Jul 22, 2021 and Wed, Oct 20, 2021 is 1.05 with a coefficient of variation of 6.45. The daily time series for the period is distributed with a sample standard deviation of 0.07, arithmetic mean of 1.03, and mean deviation of 0.06. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
      Timeline 
1
US-listed I-Mab readies Shanghai IPO - GlobalCapital07/28/2021
2
Ascendis Pharma AS Announces Upcoming Investor Presentations...08/06/2021
3
Think Research Provides Update on Proposed Acquisition of Bi...08/24/2021
4
Results of Operations09/02/2021
5
Ascendis Pharma AS Announces Upcoming Investor Presentations...09/07/2021
6
We Think Lytix Biopharma Can Afford To Drive Business Growth...09/14/2021
7
Trade Alert The CEO Director Of Cue Biopharma, Inc. , Daniel...09/28/2021
8
Why Atea Pharmaceutical Stock Is Ripping Higher Today - Nasd...10/01/2021
9
Acquisition by Christina Kay of 50000 shares of Integrated B...10/11/2021
10
Ascendis Pharma AS Announces US Commercial Launch of SKYTROF...10/15/2021

About Integrated Biopharma Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all equity instruments such as Ford or other stocks, funds, and ETFs. Alpha measures the amount that position in Integrated Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2018 2019 2020 2021 (projected)
Earnings per Basic Share0.060.140.270.29
EBITDA Margin0.0690.0810.130.11

Integrated Biopharma Upcoming Company Events

As portrayed in its financial statements, the presentation of Integrated Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Integrated Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Integrated Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Integrated Biopharma. Please utilize our Beneish M Score to check the likelihood of Integrated Biopharma's management manipulating its earnings.
Upcoming Quarterly Report11th of November 2021
Next Fiscal Quarter End30th of September 2021

Build Portfolio with Integrated Biopharma

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Integrated Biopharma Backtesting, Integrated Biopharma Valuation, Integrated Biopharma Correlation, Integrated Biopharma Hype Analysis, Integrated Biopharma Volatility, Integrated Biopharma History and analyze Integrated Biopharma Performance. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Integrated Biopharma technical otc stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Integrated Biopharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Integrated Biopharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...